Skip navigation

“Pharma is under a lot of government and public scrutiny. This industry also runs on meetings. You put those two facts together, and you can see that a meeting can expose pharma to significant risk of enforcement activity if not done correctly,” said Geoffrey Levitt, vice president and chief counsel of Wyeth Pharmaceuticals, Collegeville, Pa., during his keynote address at the Second Annual Pharmaceutical Meeting Planners Forum.

Register to view the full article

Register for and gain access to premium content including the CMI 25 Listing, our monthly digital edition, the MeetingsNet app, live and on-demand webinars, and much more.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.